Floatz logo

JCAR-017 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lyell Immunopharma, Inc.Cell therapyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

104 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
Dexasone
City of Hope Medical Center
Phase 2/3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB
Etoposide
University of California, Davis
Phase 3BB
ISOCYCLOPHOSPHAMIDE
University of California, Davis
Phase 3BB

View all 50 →

Same molecule, other indications

JCAR-017 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR is also rated in:

diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
non-Hodgkin lymphomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →